Corgenix Reports Financial Results for First Quarter of Fiscal 2010

DENVER, Nov. 12  /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC:CONX) (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, today reported sales of $2,044,967 for the first fiscal quarter ended September 30, 2009, compared with $2,001,896 for the quarter ended September 30, 2008, an increase of 2.2%.

The first quarter of fiscal 2010 produced operating income of $83,803 compared with an operating loss of $94,133 for the first quarter of fiscal 2009. The net loss for the quarter significantly improved to $6,752 or less than $0.01 per share, compared to a net loss of $340,659, or $0.01 per share, in the year earlier quarter. The primary causes of the reduced net loss for the current quarter were a $43,071 increase in sales, a $168,908 reduction in operating expenses, and a $183,915 reduction in interest expense in the current quarter versus the same quarter in the prior fiscal year.

Douglass Simpson, Corgenix CEO and President, stated, "We are extremely pleased with the performance this quarter. We showed an increase in sales over the same period in the prior year, and the previously implemented operating expense reduction plan in combination with the significantly reduced interest charges resulting from the recent debt restructuring brought us almost to the breakeven point."

Mr. Simpson added, "Our management team is continuing to focus on revenue growth while tightly controlling expenses to get us over the breakeven point and into sustained profitability."

First Quarter Fiscal 2010 Conference Call Details

Corgenix invites all those interested in hearing management's discussion of fiscal year results to join a shareholders conference call on Thursday, November 12, 2009, at 4:00 PM EST (2:00 PM MST). Interested parties can join the call by dialing [phone]. International participants may access the call by dialing [phone]. The conference code is "CORGENIX". A replay will be available for 30 days following the call by dialing [phone] for U.S. participants and [phone] for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at http://www.corgenix.com/.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.  Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission.  The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

                    SUMMARY OF FINANCIAL HIGHLIGHTS
            ($000 of U.S. dollars except shares outstanding
                        and per share amounts)

             CORGENIX MEDICAL CORPORATION AND SUBSIDIARIES
                            OPERATIONAL DATA

                                         Quarter Ended September 30
                                             2009           2008
                                             -------------------

  Net sales                                $2,045          $2,002

  Gross profit                              1,116           1,107

  Operating income (loss)                      84             (94)

  Net loss                                     (7)           (341)

  Basic and diluted loss
   per share                               $(0.00)         $(0.01)

  Basic and Diluted shares
   outstanding                         30,305,855      30,092,093





                                BALANCE SHEET DATA
                                  (in thousands)

                             September 30, 2009            June 30, 2009
                             ------------------            -------------

  Cash                              $982                         $785

  Working capital                  2,195                        2,013

  Total assets                     6,787                        6,906

  Long-term debt                     753                          744

  Total stockholders' equity       3,152                        3,113


DATASOURCE: Corgenix Medical Corporation



CONTACT:  William Critchfield, Senior VP and CFO of Corgenix Medical

Corp, [phone], ; or Media, Dan Snyders, Vice

President, Public Relations, Supervisor of Armada Medical Marketing,

[phone], ext. 230, , for Corgenix Medical

Corporation



Web Site:  http://www.corgenix.com/ 

Copyright